Ando M
Department of Medicine, Kidney Center, Tokyo Women's Medical College, Japan.
Nihon Jinzo Gakkai Shi. 1991 Aug;33(8):791-801.
Synthetic alpha-human atrial natriuretic peptide (alpha-hANP), 1 micrograms/kg, was intravenously given to 16 cirrhotic patients with ascites and 9 control subjects (CS) to investigate major factors responsible for sodium retention and refractory ascites. The following parameters were measured before and after alpha-hANP administration; such as lithium clearance (CLi) as an index of fluid delivery to the distal tuble, mean arterial pressure (MAP), urinary sodium excretion rate (UNaV), urine volume (V), glomerular filtration rate (GFR), effective renal plasma flow (ERPF), plasma renin activity (PRA), plasma aldosterone concentration (PAC), urinary excretion of prostaglandin (PG)E2, 6-keto-PGF1 alpha (6-k-PGF1 alpha), and thromboxane B2 (TxB2). Patients were divided following alpha-hANP administration into 2 groups as "good responders (GR)" and "poor responders (PR)", in which GR was defined as the group showing 2-fold-increase in UNaV. In contrast, PR had significant lower MAP (71.8 +/- 5.04 mmHg), GFR (21.3 +/- 3.90 ml/min), ERPF (158.0 +/- 43.8 ml/min), FELi (CLi/GFR; 12.6 +/- 1.26%), and higher PRA (8.72 +/- 0.99 ng/ml/h) and PAC (12.2 +/- 3.13 ng/dl) than GR. GR demonstrated almost same natriuretic response as CS with an increase of GFR and renal PGs synthesis, and a decrease of FELi despite reduction in blood pressure. However, alpha-hANP did not suppress PRA, PAC, and distal tubular reabsorption of sodium (FDRNa = 1-FENa/FELi) in cirrhotic patients, whereas suppressed in CS. UNaV correlated with FELi (r = 0.687, p = 0.01) and GFR (r = 0.777, p = 0.01). PRA correlated with FELi r = 0.669, p = 0.015), GFR (r = -0.634, p = 0.018), and MAP (r = 0.858, p = 0.001) only in cirrhosis. These results therefore indicated that hypotension caused by hemodynamic alteration and extremely stimulated renin release might effect on proximal tubular sodium reabsorption and GFR, leading to sodium retention and diuretic resistance in cirrhosis.
将1微克/千克的合成α-人心房利钠肽(α-hANP)静脉注射给16例肝硬化腹水患者和9例对照受试者(CS),以研究导致钠潴留和难治性腹水的主要因素。在注射α-hANP前后测量以下参数;如作为远端肾小管液体输送指标的锂清除率(CLi)、平均动脉压(MAP)、尿钠排泄率(UNaV)、尿量(V)、肾小球滤过率(GFR)、有效肾血浆流量(ERPF)、血浆肾素活性(PRA)、血浆醛固酮浓度(PAC)、前列腺素(PG)E2、6-酮-PGF1α(6-k-PGF1α)和血栓素B2(TxB2)的尿排泄量。注射α-hANP后,患者被分为“良好反应者(GR)”和“不良反应者(PR)”两组,其中GR被定义为UNaV增加两倍的组。相比之下,PR的MAP(71.8±5.04 mmHg)、GFR(21.3±3.90 ml/min)、ERPF(158.0±43.8 ml/min)、FELi(CLi/GFR;12.6±1.26%)显著低于GR,而PRA(8.72±0.99 ng/ml/h)和PAC(12.2±3.13 ng/dl)高于GR。GR表现出与CS几乎相同的利钠反应,GFR增加,肾PG合成增加,尽管血压降低,但FELi降低。然而,α-hANP在肝硬化患者中并未抑制PRA、PAC和远端肾小管钠重吸收(FDRNa = 1 - FENa/FELi),而在CS中则受到抑制。UNaV与FELi(r = 0.687,p = 0.01)和GFR(r = 0.777,p = 0.01)相关。仅在肝硬化患者中,PRA与FELi(r = 0.669,p = 0.015)、GFR(r = -0.634,p = 0.018)和MAP(r = 0.858,p = 0.001)相关。因此,这些结果表明,血流动力学改变引起的低血压和肾素释放的极度刺激可能影响近端肾小管钠重吸收和GFR,导致肝硬化患者钠潴留和利尿抵抗。